Following past boom/bust cycles, the oil business appears to have bottomed in February 2016 at $27 a barrel. The bruising multi-year bust in crude oil prices was the biggest reason for the world stock market sell-off from late 2015 to early 2016 of roughly 15% overall. The cruel irony of ultra-low prices is its disruptive effect on regular exploration activity. A short-term oil market depression....More>>>
Gold doesn't trade in a vacuum. Markets are connected. What happens in one often affects others. So if you want to understand what's happening with gold, you need to know what's going on in the markets that affect gold. And while lots of traders focus only on the short term, it's important to have a big-picture view, too. The big picture shows you the long-term....More>>>
I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.
Since that article was published, Alnylam stock is down....More>>>
In my whole life, I have known no wise people (over a broad subject matter area) who didn’t read all the time – none, zero. Youd be amazed at how much Warren reads – and at how much I read. My children laugh at me. They think Im a book with a couple of legs sticking out.
– Charlie Munger
Nektar Therapeutics (NASDAQ:NKTR) is one of the most robust growers....More>>>
Sanofi (NYSE:SNY)‘s stock had its “buy” rating reiterated by analysts at Deutsche Bank in a report released on Monday.
A number of other research firms have also weighed in on SNY. UBS reissued a “neutral” rating on shares of Sanofi in a report on Monday, January 15th. ValuEngine lowered Sanofi from a “buy” rating to a “hold” rating in....More>>>